Abstract
Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections. This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review. Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection. MVB was well tolerated and effective for the majority of patients in this case series.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
